Presenter Type
UNO Undergraduate Student
Major/Field of Study
Biology
Other
Molecular and Biomedical Biology
Advisor Information
Paul H. Davis
Location
MBSC304 - U
Presentation Type
Oral Presentation
Start Date
24-3-2023 1:00 PM
End Date
24-3-2023 2:15 PM
Abstract
Antibiotic resistance is one of the leading causes of concern for the world health community. Drugs used to stop various infections for years are now becoming easier for bacteria to resist due to mutations and plasmids conferring resistance. To combat this problem, new drug can help alleviate this concern. We developed an assay that allows us to screen novel drug-like compounds against bacteria in an effort to identify promising new anti-infective compounds. Our assay was designed using known drugs against a panel of gram positive and negative bacilli and cocci including S. epidermidis, P. mirabilis, N. mucosa, and E. durans. We are currently evaluating the efficacy of marinopyrroles, which are compounds derived from marine-derived streptomycetes with limited toxicity to human cells and potential activity against bacteria. We aim to report our findings of efficacy these compounds have against our surrogate pathogen panel.
Scheduling
1-2:15 p.m., 2:30 -3:45 p.m.
Included in
Biological Phenomena, Cell Phenomena, and Immunity Commons, Medical Molecular Biology Commons
DEVELOPING A BACTERIAL PANEL FOR THE EVALUATION OF NOVEL ANTI-INFECTIVE COMPOUNDS
MBSC304 - U
Antibiotic resistance is one of the leading causes of concern for the world health community. Drugs used to stop various infections for years are now becoming easier for bacteria to resist due to mutations and plasmids conferring resistance. To combat this problem, new drug can help alleviate this concern. We developed an assay that allows us to screen novel drug-like compounds against bacteria in an effort to identify promising new anti-infective compounds. Our assay was designed using known drugs against a panel of gram positive and negative bacilli and cocci including S. epidermidis, P. mirabilis, N. mucosa, and E. durans. We are currently evaluating the efficacy of marinopyrroles, which are compounds derived from marine-derived streptomycetes with limited toxicity to human cells and potential activity against bacteria. We aim to report our findings of efficacy these compounds have against our surrogate pathogen panel.